Anticancer Research

Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab

By Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Shigeki Ikushima

Cohort study of 188 peopleInterventions

6 months, multicentre

The paper

Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Shigeki Ikushima

Kobe University Hospital; Nara Prefecture General Medical Center

Anticancer Research, 31 Aug 2026

doi.org/10.21873/anticanres.18360 PubMed 42674726

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Journal of Viral Hepatitis5 Oct 2026
Becoming active is linked to lower mortality in chronic hepatitis B